Rurioctocog alfa - Shire

Drug Profile

Rurioctocog alfa - Shire

Alternative Names: Advate; Antihemophilic Factor (Recombinant); Factor VIII - Baxter Healthcare; rAHF-PFM; Recombinant anti-haemophilic factor - protein-free method; Recombinant factor VIII - protein-free

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter Healthcare Corporation
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Factor VIII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 11 Feb 2015 Registered for Haemophilia A in Qatar, Saudi Arabia, Morocco and Algeria (IV) proir to February 2015
  • 01 Jul 2014 Baxter Healthcare initiate the phase IV SPACE trial in Haemophilia A and Haemophilia B in USA (NCT02190149)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top